Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2020-12-02 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics conclut un accord de licence et de collaboration exclusif avec DongWha Pharm
Regulatory Filings Classification · 96% confidence The document announces a significant business event: Quantum Genomics signing an exclusive licensing and collaboration agreement with DongWha Pharm for the commercialization of Firibastat in South Korea. This involves financial terms (upfront payments, milestones, royalties) and strategic partnership details. This type of announcement, detailing a major transaction like a licensing deal or partnership, is best classified as a Capital/Financing Update (CAP) if it involves significant financial structuring or a major business development. Since it is a licensing deal with substantial financial components and strategic implications, it fits well under CAP, although it could also be considered a general Regulatory Filing (RNS) if no other category is more specific. Given the focus on securing future revenue streams and development rights through a structured deal, CAP is the most appropriate specific category over the general RNS.
2020-12-02 French
Fin du financement conclu avec Negma Group Ltd / Park Partners
Capital/Financing Update Classification · 99% confidence The document announces the conclusion of a financing agreement with Negma Group Ltd, detailing the amount received (€8M), the issuance of warrants (BSA), and the full settlement of debt. This content directly relates to fundraising, financing activities, and capital structure changes (specifically debt settlement via equity instruments). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA), but a specific announcement about a financing event.
2020-11-02 French
Quantum Genomics Announces End of Financing Agreement with Negma Group Ltd/Park Partners
Capital/Financing Update Classification · 99% confidence The document announces the termination and full repayment of a financing agreement involving a loan and share warrant issuance between Quantum Genomics and Negma Group Ltd/Park Partners. This action directly relates to the company's capital structure, debt repayment, and the issuance of shares (3,243,213 ordinary shares issued). This fits the definition of 'Capital/Financing Update' (CAP), as it details the conclusion of a significant financing arrangement and associated share issuance/debt settlement. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about capital structure changes.
2020-11-02 English
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals
Regulatory Filings Classification · 95% confidence The document is a press release announcing a specific corporate event: an exclusive licensing and collaboration agreement between Quantum Genomics and Xediton Pharmaceuticals regarding the drug firibastat in Canada. This type of announcement, detailing strategic partnerships, licensing deals, and associated financial terms (upfront payments, milestones, royalties), is characteristic of corporate news releases. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it details a significant business transaction and is structured as a news announcement, it best fits the general category for corporate news or regulatory announcements that don't fit a more specific financial report type. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-standard corporate announcement that isn't a core financial report or management change.
2020-10-28 English
Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Xediton Pharmaceuticals
Regulatory Filings Classification · 95% confidence The document announces a significant business event: Quantum Genomics signing an exclusive licensing and collaboration agreement with Xediton Pharmaceuticals for the commercialization of firibastat in Canada. This involves financial terms (upfront payments, milestones, royalties) and strategic partnership details. This type of announcement, detailing a major transaction or strategic move that impacts the company's future operations and value, is best classified as a general corporate announcement or a transaction related filing. Since there is no specific code for 'Licensing Agreement' or 'Strategic Partnership', and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or director dealing (DIRS), it falls under the category of a significant corporate event announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a material, non-standard announcement, although 'Capital/Financing Update' (CAP) could sometimes cover strategic deals involving future payments, the core nature here is a licensing deal. However, RNS serves as the general regulatory announcement category for material news that doesn't fit elsewhere. Given the context of a major licensing deal, RNS is the safest general classification for material news.
2020-10-28 French
Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Qilu Pharmaceutical
Regulatory Filings Classification · 95% confidence The document announces a significant business event: an exclusive licensing and collaboration agreement between Quantum Genomics and Qilu Pharmaceutical regarding the drug firibastat for the Chinese market. This involves financial terms (upfront payments, milestones, royalties) and strategic partnership details. This type of announcement, detailing a major transaction or strategic move that impacts financing or corporate structure, best fits the 'Capital/Financing Update' (CAP) category, as it secures future revenue streams and development funding, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure not covered elsewhere. However, since it details a major licensing deal involving significant financial considerations and market rights, it is fundamentally a corporate transaction announcement. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit for a major licensing deal that secures future capital/revenue, although 'RNS' (Regulatory Filings) is a common catch-all for press releases of this nature. Since the core of the announcement is securing future funding/revenue through a deal, I will lean towards CAP, but RNS is a strong secondary candidate if CAP is interpreted strictly as equity/debt issuance. Given the context of major corporate news, RNS is often used for press releases announcing deals. Let's re-evaluate: It is not a standard earnings release (ER), nor a management change (MANG), nor a dividend (DIV). It is a strategic transaction. In many databases, major licensing deals are classified under Corporate Actions or Financing. Since 'CAP' covers 'fundraising, financing activities, or capital structure changes,' and securing future revenue streams via licensing is a form of financing/capitalization strategy, CAP is plausible. However, 'RNS' is the general regulatory announcement fallback. Since this is a press release announcing a deal, and it doesn't perfectly match the specific financial transaction codes (like SHA or POS), RNS is the safest classification for a general corporate announcement of this type, unless the database strongly prioritizes the financial implication over the announcement nature. Given the structure, it reads like a standard press release announcing a material event. I will classify it as RNS as the general regulatory announcement category for material non-standard events.
2020-10-19 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.